Related Experiment Videos
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition
Eddy S Yang1, Somaira Nowsheen, Mohammad A Rahman
1Departments of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Abstract:
PARP inhibitors have gained recent attention due to their highly selective killing of BRCA1/2-mutated and DNA double-strand break (DSB) repair-deficient tumors. Unfortunately, the majority of sporadic breast cancers carry wild-type BRCA1/2 and are proficient in DSB repair. We and others have shown that BRCA1 is a nuclear/cytoplasm shuttling protein that is transiently exported from the nucleus to the cytosol upon various stimuli. Thus, we hypothesized that depletion of nuclear BRCA1 would compromise DSB repair and subsequently render sporadic tumors susceptible to PARP inhibition. Indeed, in human sporadic breast cancer cells with functional BRCA1 and proficient DSB repair, a transient nuclear depletion of BRCA1 and subsequent homologous recombination repair deficit was induced with either truncated BRCA1 or irradiation. This rendered these human sporadic breast cancer cells susceptible to PARP inhibition. These observations were confirmed genetically using mislocated BRCA1 mutants as well as in vivo in mice bearing breast tumor xenografts. These data support the potential strategy of targeting BRCA1 location to convert BRCA1-proficient sporadic tumors to be susceptible to the synthetic lethal combination with PARP inhibitors.
Insights
PARP inhibitors can now target sporadic breast cancers. Researchers found that by altering BRCA1 protein location, they could make these cancer cells vulnerable to PARP inhibitors, offering a new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- PARP inhibitors effectively treat BRCA1/2-mutated and DNA double-strand break (DSB) repair-deficient tumors.
- Most sporadic breast cancers have wild-type BRCA1/2 and proficient DSB repair, limiting PARP inhibitor efficacy.
- BRCA1 is a nuclear/cytoplasmic shuttling protein, with transient nuclear export observed under certain stimuli.
Purpose of the Study:
- To investigate if transient nuclear depletion of BRCA1 could sensitize sporadic breast cancer cells to PARP inhibitors.
- To explore targeting BRCA1 localization as a strategy to enhance PARP inhibitor effectiveness in BRCA1-proficient tumors.
Main Methods:
- Induced transient nuclear BRCA1 depletion in human sporadic breast cancer cells using truncated BRCA1 or irradiation.
- Assessed homologous recombination repair (HRR) deficiency following BRCA1 depletion.
- Evaluated the susceptibility of these cells to PARP inhibition.
- Confirmed findings genetically using mislocated BRCA1 mutants and in vivo in mouse xenograft models.
Main Results:
- Transient nuclear depletion of BRCA1 led to a homologous recombination repair deficit in sporadic breast cancer cells.
- These BRCA1-depleted cells became susceptible to PARP inhibition.
- The strategy was validated in genetically modified BRCA1 mutants and in preclinical mouse models.
Conclusions:
- Targeting BRCA1 localization represents a potential therapeutic strategy to convert BRCA1-proficient sporadic tumors into a state susceptible to PARP inhibitors.
- This approach could broaden the application of PARP inhibitors in breast cancer treatment.